BL-new-logo.jpg
SOS SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Filed Against SOS Limited
April 10, 2021 09:24 ET | Bernstein Liebhard LLP
NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities...
FStar.jpg
F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
April 10, 2021 09:22 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
KTMC-Logo_RGB.jpg
Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Ebix, Inc.
April 10, 2021 09:09 ET | Kessler Topaz Meltzer & Check LLP
RADNOR, Pa., April 10, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States...
mersana_logo.png
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting
April 10, 2021 09:00 ET | Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
LOGO.jpg
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages CytoDyn Inc. Investors to Secure Counsel Before Important May 17 Deadline – CYDY
April 10, 2021 09:00 ET | The Rosen Law Firm PA
NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTC: CYDY) between March 27, 2020 and March...
Agenus Inc. Logo
New Clinical Responses for AGEN1181 Presented at AACR
April 10, 2021 08:35 ET | Agenus Inc.
7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen in patients typically unresponsive to I-O agents ...
TCRR Logo.png
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
April 10, 2021 08:31 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
Arch Oncology Logo_RGB.jpg
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
April 10, 2021 08:31 ET | Arch Oncology
BRISBANE, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today...
Hookipa Pharma Logo Square.png
HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers
April 10, 2021 08:31 ET | Hookipa Pharma Inc
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202Early data on HB-201 monotherapy show an...
VINCERX.png
Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
April 10, 2021 08:31 ET | Vincerx Pharma, Inc.
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies on track for 1H 2022 PALO ALTO, Calif., April 10, 2021 (GLOBE NEWSWIRE)...